News Angelini rapped for criticism of EMA approval Angelini has been rapped under the UK pharma industry's code of practice for criticising licensing decisions made by the EMA and other breaches.
Market Access Indication-specific pricing in England: Business as usual? Leela Barham highlights data that shows that indication-specific pricing has been used in England for at least four years and over 60 times.
Market Access Missing metrics on the UK’s VPAG It's hard to take stock of what’s happening operationally with the UK's main pricing scheme, VPAG, given the absence of reporting by the DHSC.
News NICE backs five AI tools for bowel cancer screening Five AI technologies used during a colonoscopy exam to help detect the early signs of bowel cancer have been backed for use by the NHS in England.
News Advocate slams muted response to UK male health strategy A mental health campaigner has condemned the "stunning silence" from mainstream media in the UK as the first-ever men's health strategy is revealed.
News GSK pumps £45m into antimicrobial resistance projects GSK has revealed the six projects it will fund with the Fleming Initiative on antimicrobial resistance, set up with Imperial College London last year.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.